File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Mutliple sclerosis - updates in management

TitleMutliple sclerosis - updates in management
Authors
Issue Date2016
PublisherHong Kong College of Family Physicians. The Journal's web site is located at http://www.hkcfp.org.hk/practitioner_38.html
Citation
Hong Kong Practitioner, 2016, v. 38 n. 3, p. 83-92 How to Cite?
AbstractSummary Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system (CNS). Majority of MS patients develop functional impairment as the disease progresses. In the old days, treatment of MS is mainly confined to treatment of acute relapses, symptomatic relief and rehabilitation. While there remains no curative treatment, numerous disease modifying therapies (DMTs) have emerged in the past decade and improved the long-term outcome and quality of life of patients with relapsing-remitting MS (RRMS). In this review, we discuss the management of MS with focus on the DMTs. 摘要 多發性硬化症(MS)是中樞神經系統(CNS)的壹種 免疫引導的炎性脫髓鞘疾病。隨著病情的發展,大部分 的MS患者都會出現功能性障礙。過去MS治療的主要目 標是治療病情急性復發,紓緩癥狀和康復理療。雖然目 前仍然沒有根治的方法,但是過去十年中,有很多改善 病情的藥物(DMTs)湧現,可以改善MS病人的長期療 效,提高多次緩解而又復發病患者(RRMS)的生活質 量。這次我們主要討論MS的治療方案中DMTs的作用。
Persistent Identifierhttp://hdl.handle.net/10722/232010
ISSN
2015 SCImago Journal Rankings: 0.101

 

DC FieldValueLanguage
dc.contributor.authorLee, CY-
dc.contributor.authorChan, KH-
dc.date.accessioned2016-09-20T05:26:58Z-
dc.date.available2016-09-20T05:26:58Z-
dc.date.issued2016-
dc.identifier.citationHong Kong Practitioner, 2016, v. 38 n. 3, p. 83-92-
dc.identifier.issn1027-3948-
dc.identifier.urihttp://hdl.handle.net/10722/232010-
dc.description.abstractSummary Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system (CNS). Majority of MS patients develop functional impairment as the disease progresses. In the old days, treatment of MS is mainly confined to treatment of acute relapses, symptomatic relief and rehabilitation. While there remains no curative treatment, numerous disease modifying therapies (DMTs) have emerged in the past decade and improved the long-term outcome and quality of life of patients with relapsing-remitting MS (RRMS). In this review, we discuss the management of MS with focus on the DMTs. 摘要 多發性硬化症(MS)是中樞神經系統(CNS)的壹種 免疫引導的炎性脫髓鞘疾病。隨著病情的發展,大部分 的MS患者都會出現功能性障礙。過去MS治療的主要目 標是治療病情急性復發,紓緩癥狀和康復理療。雖然目 前仍然沒有根治的方法,但是過去十年中,有很多改善 病情的藥物(DMTs)湧現,可以改善MS病人的長期療 效,提高多次緩解而又復發病患者(RRMS)的生活質 量。這次我們主要討論MS的治療方案中DMTs的作用。-
dc.languageeng-
dc.publisherHong Kong College of Family Physicians. The Journal's web site is located at http://www.hkcfp.org.hk/practitioner_38.html-
dc.relation.ispartofHong Kong Practitioner-
dc.titleMutliple sclerosis - updates in management-
dc.typeArticle-
dc.identifier.emailChan, KH: koonho@hku.hk-
dc.identifier.authorityChan, KH=rp00537-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros263300-
dc.identifier.volume38-
dc.identifier.issue3-
dc.identifier.spage83-
dc.identifier.epage92-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats